Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma

Eric J. Formeistera, Masato Tsuchiycab, Hideki Fuijib, Svitlana Shpylevac, Igor P. Pogribnyc

a Department of Environmental Sciences and Engineering, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA
b First Department of Surgery, University of Yamanashi, Chuo, Yamanashi Prefecture, Japan
c Division of Biochemical Toxicology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR, USA

ARTICLE INFO

Article history:
Received 5 May 2010
Received in revised form 26 July 2010
Accepted 28 July 2010
Available online 22 August 2010

Keywords:
Hepatocellular carcinoma
Epigenetics
Time to recurrence

ABSTRACT

Transcriptional silencing of tumor suppressor genes and other cancer-related genes induced by promoter CpG island hypermethylation is an important epigenetic mechanism of hepatocarcinogenesis. Previous studies have established methylation profiles of hepatocellular carcinomas (HCCs) and demonstrated that methylation of several candidate genes in resected tissues may be associated with time to recurrence. The goals of our study were to test whether specific promoter methylation and mRNA levels of candidate genes, as well as global changes in DNA methylation, can be linked with time to recurrence and clinicopathological variables in a homogeneous study group of HCC patients. Forty-three tumors and 45 non-tumorous liver tissue samples from the surgical margin were obtained from HCV-positive, HBV-negative HCC patients who underwent tumor resection surgery and who were monitored for tumor recurrence thereafter (median follow-up time: 16 months (range, 0–79 months)). Methylation-specific PCR was used to assess the promoter methylation status of P16(INK4a), SOCS-1, RASSF1A, APC, GSTP1, RIZ1, and MGMT genes, while the level of LINE-1 methylation was used as marker of global DNA methylation levels. Methylation frequencies in P16(INK4a), RASSF1A, APC, GSTP1, and RIZ1 genes were significantly greater in tumors versus non-tumorous tissues. Methylation of RIZ1 in non-tumorous tissues was significantly associated with time to recurrence. Additionally, genomic DNA was significantly more hypomethylated in tumorous tissues, and this change was associated with shorter recurrence, but not with clinicopathological features. In conclusion, this study supports the role of aberrant methylation in the pathobiology of HCV-positive HCCs. The finding that RIZ1 methylation and increased levels of LINE-1 hypomethylation in non-tumorous tissues are associated with time to recurrence underscores the importance of assessing the epigenetic state of the liver remnant.

© 2010 Elsevier B.V. All rights reserved.

1. Introduction

Hepatocellular carcinoma (HCC) is the fifth most common and the third most fatal malignancy worldwide [1]. While the incidence of many cancers is declining, HCC incidence continues on the upward trajectory over the last three decades in many countries, including the U.S. and Japan. Over 80% of hepatocellular carcinoma cases are attributable to four major causes: infection with hepatitis C (HCV) or B (HBV) viruses, chronic alcohol consumption, and/or exposure to aflatoxin B1 [2]. Profound geographic variation in HCC incidence and etiology is well known; the highest density of cases occur in Southeast Asia and are associated primarily with chronic HBV (China), or HCV (Japan) infection [3,4]. It is widely believed that the continuous epidemic of HCV largely accounts for the observed increase in HCC incidence [4–6]. Clinical management of HCC is challenging due both to the lack of diagnostic and prognostic biomarkers and resistance of HCC to chemotherapy and radiation treatment. Tumor resection and ablation are common clinical choices; however, survival is poor, with a 5-year recurrence rate of over 75% and a 5-year survival as low as 50% [7,8]. Though...
clinopathological features are useful in identifying patients who are at-risk for recurrence, molecular predictors have also been proposed [9,10].

In liver and other tissues, gene-specific promoter hypermethylation is increasingly recognized as a common epigenetic event throughout all stages of carcinogenesis [11–13]. Several studies have shown aberrant hypermethylation of P16(INK4a), RASSF1A, SOCS-1, GSTP1, APC, RIZ1, and MGMT in HCC [14–19]. Furthermore, methylation profiling of HCC has been successful in characterizing some of the antecedent methylation changes of specific genes in cancer initiation and promotion, aberrations that have been shown to accompany distinct, sequential histopathologic steps during hepatocarcinogenesis [17,20,21]. This has been crucial in providing evidence for field cancerization of HCC, the notion that HCC recurrences represent formations of additional field tumors that develop from patches of genetically and epigenetically dysregulated pre-neoplastic cells in the diseased liver [22,23]. In addition, it has been suggested that the methylation status of many of these genes can be predictive of recurrence–free and overall survival, albeit there is some inconsistency between the studies for individual genes as predictive biomarkers. Even in relatively small study groups (60 pairs of tumors and adjacent non-tumorous tissues or fewer), the methylation status of GSTP1, CDH1, P16(INK4a), CRABPI, and SYK in tumors and tissues corresponds to shortened overall survival [17,24,25], while specific promoter hypermethylation of MGMT in tumors and RIZ1 in the non-tumorous tissues have been reported as associated with time to recurrence [18].

Underpinning the complex and aberrant epigenetic milieu of hepatocarcinogenesis, gene-specific hypermethylation is often accompanied by global genomic hypomethylation, an epigenetic event associated with oncogene activation and overall genomic instability during carcinogenesis [26]. Though several studies offer conflicting reports of the relationship between global DNA hypomethylation and hypermethylation of specific genes [25,27], it has been demonstrated that global DNA hypomethylation in tumors is inversely correlated with overall patient survival in studies consisting of 60 [26] or 85 samples [28].

However, most of the previously reported studies that have examined epigenetic changes in HCC consisted of patient study groups that were heterogeneous with respect to the underlying disease etiology. Additionally, epigenetic studies of HCC only seldom include simultaneous analyses of both methylation status and gene expression levels. Thus, characterization of epigenetic and gene expression changes specific to HCV-positive/HBV-negative disease etiology and identification of genes whose promoter methylation status might be predictive of time to recurrence were goals of this study. We determined both global DNA methylation levels and gene-specific methylation status in tumors and adjacent non-tumorous tissues in an etiologically and geographically distinct study group of HCC patients, compared the association between promoter methylation and gene expression, and analyzed the relationship between these epigenetic aberrations and both clinicopathological variables and time to recurrence.

2. Materials and methods

2.1. Patient study group and sample collection

The study group consisted of 49 HCV-positive, HBV-negative subjects with clinicopathological features are useful in identifying patients who are at-risk for recurrence, molecular predictors have also been proposed [9,10].

In liver and other tissues, gene-specific promoter hypermethylation is increasingly recognized as a common epigenetic event throughout all stages of carcinogenesis [11–13]. Several studies have shown aberrant hypermethylation of P16(INK4a), RASSF1A, SOCS-1, GSTP1, APC, RIZ1, and MGMT in HCC [14–19]. Furthermore, methylation profiling of HCC has been successful in characterizing some of the antecedent methylation changes of specific genes in cancer initiation and promotion, aberrations that have been shown to accompany distinct, sequential histopathologic steps during hepatocarcinogenesis [17,20,21]. This has been crucial in providing evidence for field cancerization of HCC, the notion that HCC recurrences represent formations of additional field tumors that develop from patches of genetically and epigenetically dysregulated pre-neoplastic cells in the diseased liver [22,23]. In addition, it has been suggested that the methylation status of many of these genes can be predictive of recurrence–free and overall survival, albeit there is some inconsistency between the studies for individual genes as predictive biomarkers. Even in relatively small study groups (60 pairs of tumors and adjacent non-tumorous tissues or fewer), the methylation status of GSTP1, CDH1, P16(INK4a), CRABPI, and SYK in tumors and tissues corresponds to shortened overall survival [17,24,25], while specific promoter hypermethylation of MGMT in tumors and RIZ1 in the non-tumorous tissues have been reported as associated with time to recurrence [18].

Underpinning the complex and aberrant epigenetic milieu of hepatocarcinogenesis, gene-specific hypermethylation is often accompanied by global genomic hypomethylation, an epigenetic event associated with oncogene activation and overall genomic instability during carcinogenesis [26]. Though several studies offer conflicting reports of the relationship between global DNA hypomethylation and hypermethylation of specific genes [25,27], it has been demonstrated that global DNA hypomethylation in tumors is inversely correlated with overall patient survival in studies consisting of 60 [26] or 85 samples [28].

However, most of the previously reported studies that have examined epigenetic changes in HCC consisted of patient study groups that were heterogeneous with respect to the underlying disease etiology. Additionally, epigenetic studies of HCC only seldom include simultaneous analyses of both methylation status and gene expression levels. Thus, characterization of epigenetic and gene expression changes specific to HCV-positive/HBV-negative disease etiology and identification of genes whose promoter methylation status might be predictive of time to recurrence were goals of this study. We determined both global DNA methylation levels and gene-specific methylation status in tumors and adjacent non-tumorous tissues in an etiologically and geographically distinct study group of HCC patients, compared the association between promoter methylation and gene expression, and analyzed the relationship between these epigenetic aberrations and both clinicopathological variables and time to recurrence.
determine associations between the methylation status of each gene and clinicopathological variables, to examine differences in gene expression according to methylation status, and to compare LINE-1 methylation levels between samples. Univariate and multivariate Cox proportional hazards models were used to investigate relationships between premutation methylation status, gene expression, and clinicopathological data with time to recurrence with JMP software (version 6, SAS Institute Inc., Cary, NC). Kaplan–Meier recurrence-free survival curves were generated using software from GraphPad Prism (v. 5, San Diego, CA). A p-value < 0.05 was considered statistically significant.

3. Results

3.1. Clinicopathological characteristics of the patient study group

In all of the statistical analyses performed in this study, the full study group (49 subjects) was divided into patients for which DNA and gene expression data from HCC samples (n = 43), or non-tumorous samples (n = 45) were available. There were 39 paired samples. The patients in each sub-group did not differ significantly with respect to any of the clinicopathological variables (data not shown). As a first step to consider the relationship between the typical clinicopathological variables of HCC resection patients, including demographic characteristics, tumor information, laboratory results, and the time to recurrence, univariate Cox proportional hazards analyses were performed. In both sub-groups, tumor number, tumor diameter, and tumor stage were significantly associated with an earlier recurrence (Supplemental Table 2).

3.2. Gene-specific promoter methylation analysis in tumors and non-tumorous tissues

Aberrant promoter methylation of P16(INK4a), SOCS-1, RASSF1A, APC, GSTP1, RIZ1, and MGMT is commonly reported in epigenetic studies of HCC [14–19]. Here, we examined the methylation profile of these 7 genes, which are associated with a number of dysregulated pathways during carcinogenesis, in both tumors and non-tumorous samples from HCV-positive HCC patients (Table 1). All of these genes were almost entirely unmethylated in the DNA from control human livers; however, the frequencies of methylation of all genes, except MGMT, were significantly higher (p < 0.05, Fisher’s exact test) in tumors samples as compared to control liver. In non-tumorous samples, the methylation frequencies of only SOCS-1 and RASSF1A were significantly higher than those in controls.

We applied McNemar’s version of the chi-square test to compare the methylation frequencies between the 39 pairs of tumors and non-tumorous tissue samples. The frequencies of methylation of p16(INK4a), RASSF1A, APC, GSTP1, and RIZ1 were significantly higher in tumors as compared to non-tumorous tissues, while the methylation frequency of MGMT showed an opposite trend, and SOCS-1 exhibited an equally high methylation frequency in both sub-groups (Table 1).

In addition to identifying differences in gene-specific frequencies of methylation between tumors and non-tumorous tissues, we were interested in investigating the significance of the multiplicity of methylated genes in the pathogenesis of HCC. Fig. 1 shows the distribution of the number of samples with multiple methylated genes in control, non-tumorous and tumors tissues. There was a statistically significant increase in the number of methylated genes as pathology progressed from normal to neoplastic, as the average number of methylated genes (±SD) in control, non-tumorous, and tumors samples was 0.1 (±0.3), 2.2 (±1.0), and 4.9 (±1.0), respectively (p < 0.001, unpaired t-tests).

3.3. Analysis of methylation accordance between tumors and non-tumorous tissues

The nonzero number of non-tumorous samples for which promoter methylation was detected in each gene examined and the significantly higher methylation frequencies of SOCS-1 and RASSF1A in non-tumorous tissues relative to control liver provide evidence for field cancerization [18,23] within the preneoplastic tissue adjacent to HCC. To further explore this concept, we determined the accordance between methylation status in tumors and

<table>
<thead>
<tr>
<th>Gene</th>
<th>Tumorous samples (n=43)</th>
<th>No. T samples methylated (%)</th>
<th>Hazard ratio</th>
<th>95% CI</th>
<th>p-value</th>
<th>Non-tumorous samples (n=45)</th>
<th>No. NT samples methylated (%)</th>
<th>Hazard ratio</th>
<th>95% CI</th>
<th>p-value</th>
<th>No. CTL samples methylated (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>p16**</td>
<td>34/43 (79%)</td>
<td>0.88</td>
<td>0.59–1.40</td>
<td>0.57</td>
<td></td>
<td>7/45 (16%)</td>
<td>0.85</td>
<td>0.50–1.32</td>
<td>0.50</td>
<td>0/10 (0%)</td>
<td></td>
</tr>
<tr>
<td>SOCS-1</td>
<td>39/43 (91%)</td>
<td>1.05</td>
<td>0.63–2.16</td>
<td>0.86</td>
<td></td>
<td>41/45 (91%)</td>
<td>0.60</td>
<td>0.35–1.25</td>
<td>0.15</td>
<td>0/10 (0%)</td>
<td></td>
</tr>
<tr>
<td>RASSF1A</td>
<td>43/43 (100%)</td>
<td>n/a (all methylated)</td>
<td></td>
<td></td>
<td></td>
<td>31/45 (69%)</td>
<td>0.96</td>
<td>0.68–1.39</td>
<td>0.82</td>
<td>0/10 (0%)</td>
<td></td>
</tr>
<tr>
<td>APC**</td>
<td>40/43 (93%)</td>
<td>0.91</td>
<td>0.49–2.26</td>
<td>0.79</td>
<td></td>
<td>9/45 (20%)</td>
<td>1.41</td>
<td>0.88–2.14</td>
<td>0.15</td>
<td>1/10 (10%)</td>
<td></td>
</tr>
<tr>
<td>GSTP1**</td>
<td>23/43 (53%)</td>
<td>0.80</td>
<td>0.56–1.13</td>
<td>0.20</td>
<td></td>
<td>2/45 (4%)</td>
<td>0.74</td>
<td>0.18–1.61</td>
<td>0.52</td>
<td>0/10 (0%)</td>
<td></td>
</tr>
<tr>
<td>RIZ1**</td>
<td>33/43 (76%)</td>
<td>0.92</td>
<td>0.62–1.46</td>
<td>0.71</td>
<td></td>
<td>4/45 (9%)</td>
<td>2.29</td>
<td>1.22–3.83</td>
<td>0.01</td>
<td>0/10 (0%)</td>
<td></td>
</tr>
<tr>
<td>MGMT*</td>
<td>0/43 (0%)</td>
<td>n/a (all unmethylated)</td>
<td></td>
<td></td>
<td></td>
<td>7/45 (16%)</td>
<td>1.17</td>
<td>0.44–2.67</td>
<td>0.73</td>
<td>0/10 (0%)</td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Frequency of promoter methylation of tumor suppressor genes in tumorous, non-tumorous, and control liver DNA and association with time to recurrence.

* T, tumors; NT, non-tumorous; CTL control; ** p<0.05, and *** p<0.001 for McNemar’s chi-Square test between paired tumors and non-tumorous tissues. Associations with recurrence-free survival were tested using univariate Cox proportional hazard models; p-values are from Log-Rank tests.
Table 2

<table>
<thead>
<tr>
<th>Gene</th>
<th>T−/NT− (%)</th>
<th>T−/NT+ (%)</th>
<th>T+/NT− (%)</th>
<th>T+/NT+ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>p16</td>
<td>7 (18%)</td>
<td>1 (3%)</td>
<td>25 (64%)</td>
<td>6 (15%)</td>
</tr>
<tr>
<td>SOCS-1</td>
<td>1 (3%)</td>
<td>3 (8%)</td>
<td>3 (8%)</td>
<td>32 (82%)</td>
</tr>
<tr>
<td>RASSF1A</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>12 (31%)</td>
<td>27 (69%)</td>
</tr>
<tr>
<td>APC</td>
<td>2 (5%)</td>
<td>0 (0%)</td>
<td>29 (74%)</td>
<td>8 (21%)</td>
</tr>
<tr>
<td>GSTP1</td>
<td>17 (44%)</td>
<td>1 (3%)</td>
<td>20 (51%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>RIZ1</td>
<td>8 (21%)</td>
<td>1 (3%)</td>
<td>27 (69%)</td>
<td>3 (8%)</td>
</tr>
<tr>
<td>MGMT</td>
<td>33 (85%)</td>
<td>6 (15%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

Average % 25% 4% 42% 28%

T, tumorous; NT, non-tumorous; (−) indicates no promoter methylation and (+) indicates promoter methylation in tumorous or non-tumorous tissues.

and non-tumorous tissue from the same patient for each gene. To characterize a tumor as monoclonal or polyclonal in origin [33], a comparison of the methylation status between paired tumorous and non-tumorous samples was performed. There are four possible combinations of methylation status for each tissue pair: the gene is methylated in both the non-tumorous tissue and the corresponding tumorous tissue (T+/NT+), the gene is methylated in the tumorous, but not in non-tumorous tissue (T+/NT−), the gene is methylated in neither tissue (T−/NT−), or the gene is methylated in the non-tumorous, but not the tumorous tissue (T−/NT+). The first three combinations can be identified as accordant and have been suggested to be of monoclonal origin [18]. When comparing each sample pair type by each specific gene (Table 2), the majority of tissues were either T+/NT− (avg. 42%) or T+/NT+ (avg. 28%). However, at least one sample pair was discordant (that is, T−/NT+) for methylation in all genes except RASSF1A and APC, indicating that these tumors were polyclonally derived and providing support for multicentric HCC tumorigenesis, as described by others [34].

Additionally, we analyzed accordance between the methylation status in tumorous and corresponding non-tumorous tissues for all 7 genes and found that 28 (72%) of the pairs were accordant for all genes. Of the 11 pairs that were not accordant for all genes, 10 were discordant for only one gene (Supplemental Fig. 2). Moreover, the 11 discordant pairs were obtained from patients who experienced an average time to recurrence that was longer than those patients harboring accordant tumorous/non-tumorous tissue pairs (29.3 months versus 20.9 months), though this relationship was not statistically significant (p = 0.20, data not shown).

3.4. Association between promoter methylation status, time to recurrence, and clinicopathological variables

To investigate the association between gene methylation status and time to recurrence, we performed univariate Cox proportional hazards analyses for all genes in both the tumorous and non-tumorous sub-groups. We observed that only hypermethylation of RIZ1 in non-tumorous tissues was significantly associated with a higher risk for earlier recurrence (HR = 2.29; 95% CI = 1.22–3.83; p = 0.01, Table 1). However, this relationship was not significant in the multivariate analysis when other significant univariate clinicopathological predictors (tumor diameter, tumor number, and tumor stage) were included (data not shown). Fig. 2 shows Kaplan–Meier recurrence-free survival curves according to the methylation status of RIZ1 and P16(INK4a), a representative non-significant gene, in tumorous and non-tumorous tissues. Despite the prominent shift in the number of methylated genes as pathology progressed from control to tumorous tissue (Fig. 1), univariate
Cox proportional hazards analyses revealed that the number of methylated genes per tumor sample did not dispose the patient to a higher risk for earlier recurrence (data not shown). In addition, we examined the relationship between gene methylation status and clinicopathological variables (Supplemental Table 3). Only a few significant \( p < 0.05 \) relationships were found.

### 3.5. Global DNA methylation analysis in tumorous and non-tumorous tissues

Though promoter hypermethylation of specific genes is a common epigenetic event in hepatocarcinogenesis, this specific aberration is often concurrent with global DNA hypomethylation [27]. Therefore, in addition to examining gene-specific hypermethylation, global DNA hypomethylation in tumorous and non-tumorous tissues was assessed by analyzing the level of LINE-1 methylation as a marker for global DNA methylation levels. LINE-1 was significantly \( p < 0.001 \) more hypomethylated in tumorous tissues as compared to non-tumorous tissues (Fig. 3A). When patients were divided into those with an earlier recurrence (<1 year) or later recurrence (>1 year), the level of hypomethylation in the tumorous samples was significantly higher in patients with earlier recurrences. The same was true when assigning 2 years as the cutoff between early and late recurrence (Fig. 3B). When patients with HCV-associated HCC were sub-divided into two groups based on the median value of LINE-1 hypomethylation in non-tumorous tissues, a nearly significant difference in time to recurrence outcome between the groups was observed; patients with higher hypomethylation experienced earlier recurrences \( p = 0.06 \). The level of LINE-1 hypomethylation in tumorous tissues was also significantly inversely correlated with ALT levels (data not shown). In non-tumorous tissues, LINE-1 hypomethylation was significantly directly correlated with tumor diameter \( r^2 = 0.11, p = 0.03 \), but not with any other clinicopathological variables (data not shown). No other correlations with clinicopathological variables were observed (Supplemental Table 4). Univariate Cox proportional hazards analyses revealed that the level of global DNA hypomethylation in either tissue type was not significantly related to time to recurrence. There was also no association between the degree of LINE-1 hypomethylation and the methylation status of any of the 7 genes, or the number of genes methylated in either the tumorous or non-tumorous sub-group (Supplemental Table 4).

### 3.6. Variable concordance between gene expression and promoter methylation status in tumorous and non-tumorous tissues

Though the functional consequence of promoter methylation is frequently presumed to be a reduction in gene expression, this relationship is only infrequently evaluated in clinical studies. Using microarray data collected from the same tumorous and non-tumorous samples, we compared the promoter methylation status of the 7 candidate genes with their mRNA levels. There were significant differences in the expression level for 6 genes between tumorous and non-tumorous tissues (Fig. 4, Supplemental Table 5). When tumorous and non-tumorous sub-groups were pooled, corresponding gene expression levels were significantly lower in samples with \( RIZ1 \) methylation \( p < 0.01 \) and \( GSTP1 \) methylation \( p = 0.01 \). Interestingly, \( P16 \) expression was significantly higher in methylated versus unmethylated tissues, a relationship that was also true when analyzing only tumorous tissues. Significant concordance between lower gene expression and methylation of \( MGMT \) was also observed in the non-tumorous sub-group (Supplemental Table 5). The univariate Cox proportional hazards models analyses of the association between gene expression and time to recurrence...
showed that only one probe for the SOCS-1 gene was significant, and only in non-tumorous tissues (HR = 8.09; 95% CI = 1.11–52.5; \( p = 0.04 \)). For this same probe, gene expression in methylated tissues was marginally significantly lower (\( p = 0.06 \)) in pooled tumorous and non-tumorous tissues (Supplemental Table 5).

We previously reported a strong predictive time to recurrence signature based on the gene expression data of 91 genes in non-tumorous tissues from patients with a late (>1 year) recurrence [29]. This signature was independently prognostic in the multivariate Cox proportional hazards analysis that included both tumor and non-tumorous (\( p = 0.06 \)) in pooled tumorous and non-tumorous samples (\( p = 0.04 \)). For this same probe, gene expression in methylated tissues was marginally significantly lower (\( p = 0.06 \)) in pooled tumorous and non-tumorous tissues (Supplemental Table 5).

We examined gene-specific methylation of selected genes, including P16(INK4a), SOCS-1, RASSF1A, APC, GSTP1, RIZ1, and MGMT based on their relevance in several cancer pathways (e.g., cell cycle regulation, inhibition of the Ras pathway, xenobiotic metabolism and DNA repair) that are frequently disturbed in HCC [14–19]. Consistent with other studies, we observed higher frequencies of promoter methylation in tumorous versus non-tumorous tissues for P16(INK4a), RASSF1A, APC, GSTP1, and RIZ1. The high frequency of methylation in tumorous tissues for all genes, except MGMT, as well as the high average number of genes methylated per sample (4.9), suggest that HCV-associated HCC is characterized by concordant methylation of multiple genes, epigenetic events which might signify the emergence of the CpG island methylator phenotype, an important feature of many human neoplasms [35]. Interestingly, however, both SOCS-1 and RASSF1A genes were methylated at high frequencies in non-tumorous tissues, and MGMT was significantly more methylated in non-tumorous tissues, indicating that epigenetic aberrations in surrounding non-neoplastic tissues are important events in HCC tumorigenesis [20,36]. Indeed, all of the genes examined were methylated in at least two of the non-tumorous samples, and the average number of methylated genes in non-tumorous samples was 2.2. Similarly, other researchers have demonstrated that promoter hypermethylation is far more frequent in non-tumorous HCV-positive liver as compared to non-tumorous HCV-negative liver [20]. Thus, the aberrant gene-specific methylation profile in this etiologically distinct subclass of HCC reveals the importance of epigenetic changes in virus-associated hepatocarcinogenesis. In addition, the high methylation frequencies observed in the surgical margin of non-tumorous liver tissue suggest epigenetic evidence for field cancerization in HCC and may be related to the rapidity of HCC recurrence following resection.

A major focus of our study was to elucidate the relationship between changes in global and/or gene-specific DNA methylation and time to recurrence. The potential relevance of using methylation status as a predictor for overall or time to recurrence has been explored by several investigators, and with encouraging results. Specifically, hypermethylation of GSTP1 and P16 was previously reported as significantly associated with reduced overall survival [17,24], while MGMT hypermethylation in tumorous tissues and RIZ1 hypermethylation in non-tumorous tissues were significantly related to earlier recurrence [18]. The results of our study demonstrate that only methylation of RIZ1 in non-tumorous tissues was.
associated with an increased risk for earlier recurrence. This serves as an independent confirmation of the association between RIZ1 promoter hypermethylation and shorter time to recurrence and is consistent with the finding that RIZ1 promoter hypermethylation is an early event in hepatocarcinogenesis [36]. We optimistically posit that RIZ1 hypermethylation tested in biopsy specimens may serve as a pre-clinical marker of liver tumor development. We caution, however, that the number of genes examined in our study was limited and perhaps the addition of other candidate genes may yield better correlations between the number of methylated genes and time to recurrence. Importantly, varying results between this study and others demonstrate how specific epigenetic changes may be reflective of the distinct background liver disease of HCC.

Several groups have recently demonstrated that global DNA hypomethylation accompanies specific gene hypermethylation in HCC and contributes to carcinogenesis via protooncogene activation and overall genomic instability [25–27]. We also show that genomic hypomethylation, as assessed by LINE-1 methylation levels, occurs concomitantly with specific gene hypermethylation in tumors. This finding corresponds to the results of the study conducted by Calvisi et al. [26], demonstrating that hypermethylation of CpG islands is related to the levels of LINE-1 hypomethylation in HCC.

Despite not finding a significant association between LINE-1 hypomethylation levels and time to recurrence, we observed that the level of hypomethylation in tumors from patients with earlier recurrences was significantly higher than that in subjects with later recurrences in separate analyses that used either 1 year or 2 years as the cutoff for early versus late recurrence. LINE-1 methylation levels in non-tumorous tissues did not differ after dichotomization according to recurrence time, in agreement with the study conducted by Kim et al. [27], demonstrating that hypermethylation of CpG islands is related to the levels of LINE-1 hypomethylation in HCC.

Furthermore, our study combined epigenetic analyses with whole genome microarray data to investigate molecular changes during hepatocarcinogenesis. Because it is well recognized that promoter hypermethylation may result in transcriptional repression, we aimed to characterize the relationship between methylation of specific genes and corresponding mRNA levels. We hypothesized that tissues in which gene promoters were methylated would also show decreased expression. Even though we found significant differences in gene expression between tumorous and non-tumorous tissues for all of the genes (except for APC), RIZ1 and GSTP1 were the only genes whose expression was significantly lower in methylated samples when examining both tumorous and non-tumorous samples together. Counter-intuitively, expression of P16 was actually significantly higher in samples showing P16 methylation. When analyzed separately in the tumorous sub-group, this relationship was upheld. Additionally, MGMT expression was significantly lower in methylated samples in the non-tumorous sub-group. RIZ1 hypermethylation was significantly associated with reduced time to recurrence, and RIZ1 gene expression was lower in hypermethylated samples, a relationship that has been demonstrated by others [37]. However, the univariate Cox proportional hazards analyses showed that gene expression of RIZ1 and 5 of the other genes analyzed was not associated with time to recurrence; only SOCS-1 expression in non-tumorous samples was significantly associated with earlier recurrence.

The lack of the hypothesized correlation between promoter hypermethylation and reduced gene expression in 5 of the 7 genes analyzed could be the result of examining only a limited number of CpG sites in the gene promoters. Additionally, promoter hypermethylation is only one of several epigenetic modifications affecting gene expression. Because mRNA levels are quite dynamic, it is reasonable to suggest that other compensatory processes are operating as cells attempt to reverse changes in expression due to promoter hypermethylation. In the dysfunctional biological and molecular context of cancer, there could be a myriad of mechanisms responsible for influencing gene expression, including miRNA binding, chromatin and histone modifications, and larger chromosomal aberrations, such as loss of heterozygosity. Finally, the over-sensitivity of methylation-specific PCR for detecting methylation might partially explain the absence of the expected correlation between promoter methylation status and gene expression.

To further investigate the apparent lack of a direct relationship between methylation status and gene expression, we attempted the converse approach, and selected candidates for methylation analysis based on expression profiles of genes which were related to time to recurrence. Except for GATA-4, all of the 9 genes identified with putative promoter CpG islands had not previously been reported in the literature, and thus were novel targets for methylation analyses. However, none of the genes were methylated in a subset of tumorous and non-tumorous tissues, including GATA-4, which was previously reported to be methylated in 58% of HCC cases [26]. Thus, overall, we conclude that there is a lack of agreement between promoter methylation status and gene expression in a group of HCV-positive HCC patients, and we reason that assessment of methylation status alone may not be sufficient for explaining the downstream cascade of events leading to dysregulated gene expression in HCV-associated hepatocarcinogenesis.

From a genome-wide perspective, then, it appears that gene expression signatures of time to recurrence are more difficult to characterize, because a host of other mechanisms that affect gene expression are operating, perhaps undetectably. By focusing within a smaller, more gene-specific context, however, patterns of methylation appear to be more stable and robust markers of the sequential accumulation of molecular aberrations along multistep hepatocarcinogenesis. Biomarkers such as RIZ1 hypermethylation in non-tumorous tissues may serve a more clinically useful role, as its association with earlier recurrence or as an early event in tumorigenesis is reproducible between studies, even within distinct, independent study groups [36,37].

In summary, we examined some of the epigenetic changes that sequentially accumulate during HCV-related hepatocarcinogenesis and demonstrate the technical and practical challenges of relating promoter methylation status to corresponding gene expression levels and time to recurrence. Multiple genes in multiple pathways known to be dysregulated during tumorigenesis were hypermethylated in both tumorous and non-tumorous tissues. Additionally, changes in global DNA methylation levels were more pronounced in tumorous tissues. Together, our epigenetic data establishes an aberrant methylation profile in an etiologically distinct group of HCV-positive HCC cases. The finding that RIZ1 methylation and increased levels of LINE-1 hypomethylation in non-tumorous tissues are associated with time to recurrence underscores the importance of assessing the epigenetic state of the liver remnant following tumor resection.

**Conflict of interest statement**

The authors declare that there are no conflicts of interest.
Acknowledgments

Financial support for these studies was provided, in part, by grants from the National Institutes of Health: R01 AA016285 and R01 ES015241. EJF was also supported, in part, by the UNC Graduate School Competitive Merit Assistance.

Appendix A. Supplementary data


References